Table 1. Prevalence of CTCs at baseline and their association with clinical characteristics (n=136).
|
CTC numbers (per 7.5 ml) (n% of patients)a |
||||||
|---|---|---|---|---|---|---|
| Variable | No. of patients | ⩾1 | ⩾2 | ⩾3 | ⩾4 | ⩾5 |
| All AGCs | 136 | 76 (55.9) | 65 (47.8) | 57 (41.9) | 52 (38.2) | 48 (35.3) |
|
Primary tumour site | ||||||
| Stomach | 85 | 49 (57.6) | 45 (52.9) | 42 (49.4) | 39 (45.9) | 37 (43.5) |
| Gastroesophageal junction | 51 | 27 (52.9) | 20 (39.2) | 15 (29.4) | 13 (25.5) | 11 (21.6) |
| (P-value)b | (0.593) | (0.121) | (0.022) | (0.018) | (0.009) | |
|
Lauren classificationc | ||||||
| Intestinal | 57 | 29 (50.9) | 25 (43.9) | 22 (38.6) | 20 (35.1) | 18 (31.6) |
| Diffuse | 42 | 24 (57.1) | 22 (52.4) | 20 (47.6) | 17 (40.5) | 15 (35.7) |
| Mixed | 32 | 20 (62.5) | 16 (50.0) | 13 (40.6) | 13 (40.6) | 13 (40.6) |
| (P-value) | (0.556) | (0.682) | (0.657) | (0.816) | 0.689) | |
|
Sites of metastasis | ||||||
| Liver | ||||||
| Yes | 36 | 25 (69.4) | 20 (55.6) | 20 (55.6) | 20 (55.6) | 18 (50.0) |
| No | 100 | 51 (51.0) | 45 (45.0) | 37 (37.0) | 32 (32.0) | 30 (30.0) |
| (P-value)b | (0.042) | (0.186) | (0.042) | (0.011) | (0.027) | |
| Peritoneum | ||||||
| Yes | 24 | 15 (62.5) | 12 (50.0) | 10 (41.7) | 11 (45.8) | 8 (33.3) |
| No | 112 | 61 (54.5) | 53 (47.3) | 46 (40.9) | 46 (41.1) | 44 (39.3) |
| (P-value) | (0.313) | (0.494) | (0.605) | (0.417) | (0.382) | |
|
HER2 statusd | ||||||
| Positive | 29 | 17 (58.6) | 16 (55.2) | 14 (48.3) | 14 (48.3) | 12 (41.4) |
| Negative | 101 | 55 (54.5) | 45 (44.6) | 40 (39.6) | 36 (35.6) | 34 (33.7) |
| (P-value) | (0.691) | (0.313) | (0.404) | (0.218) | (0.444) | |
Abbreviations: AGC=advanced gastric cancer; HER2=human epidermal growth factor receptor 2.
a
Unless otherwise indicated.
b
The values highlighted in bold were statistically significant (P<0.05).
c
Five patients had unavailable Lauren classifications.
d
Six patients had unavailable HER2 status information.